Patents by Inventor Liliana Maruri Avidal

Liliana Maruri Avidal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RECOMBINANT VACCINIA VIRUS
    Publication number: 20230201283
    Abstract: The present disclosure provides a replication-competent, recombinant oncolytic vaccinia virus (RVV), compositions comprising the RVV, and use of the RVV or composition for inducing oncolysis in an individual having a tumor.
    Type: Application
    Filed: January 5, 2021
    Publication date: June 29, 2023
    Inventors: Joseph John Binder, Michael Dale Eisenbraun, Douglas Hanahan, David H. Kirn, Clare Lees, Prajit Limsirichai, Liliana Maruri Avidal
  • Recombinant vaccinia virus and methods of use thereof
    Patent number: 11685904
    Abstract: The present disclosure provides a replication-competent, recombinant oncolytic vaccinia virus, compositions comprising the vaccinia virus, and use of the vaccinia virus or composition for inducing oncolysis in an individual having a tumor.
    Type: Grant
    Filed: February 10, 2020
    Date of Patent: June 27, 2023
    Assignee: Ignite Immunotherapy, Inc.
    Inventors: David H. Kirn, Liliana Maruri Avidal, Prajit Limsirichai
  • VARIANT ONCOLYTIC VACCINIA VIRUS AND METHODS OF USE THEREOF
    Publication number: 20230002740
    Abstract: The present disclosure provides a replication-competent, recombinant oncolytic vaccinia virus (OVV) comprising one of more of a) a nucleotide sequence encoding a variant A33 polypeptide, b) a nucleotide sequence encoding a variant A34 polypeptide, and c) a nucleotide sequence encoding a variant B5 polypeptide, wherein the variant A33, variant A34, and variant B5 polypeptides comprise one or more amino acid substitutions that provide for enhanced virus spreading or enhanced EEV production as compared with a virus encoding a corresponding wild-type A33, A 34, and B5 polypeptide. The present disclosure also provides compositions comprising the OVV and use of the OVV or the composition for inducing oncolysis in an individual having a tumor.
    Type: Application
    Filed: December 9, 2020
    Publication date: January 5, 2023
    Inventors: David H. Kirn, Liliana Maruri Avidal, Todd Brandon Slaby, Darin Michael Abbadessa, Nathaniel Phillip Gulizia, Melissa A. Kotterman
  • Recombinant vaccinia virus and methods of use thereof
    Patent number: 11529402
    Abstract: The present disclosure provides a replication-competent, recombinant oncolytic vaccinia virus; and compositions comprising the replication-competent, recombinant oncolytic vaccinia virus. The present disclosure also provides use of the vaccinia virus or composition for inducing oncolysis in an individual having a tumor.
    Type: Grant
    Filed: January 9, 2020
    Date of Patent: December 20, 2022
    Assignee: Ignite Immunotherapy, Inc.
    Inventors: Douglas Hanahan, David H. Kirn, Liliana Maruri Avidal, Michael D. Eisenbraun, Joseph J. Binder, Clare Lees
  • RECOMBINANT VACCINIA VIRUS AND METHODS OF USE THEREOF
    Publication number: 20200263145
    Abstract: The present disclosure provides a replication-competent, recombinant oncolytic vaccinia virus, compositions comprising the vaccinia virus, and use of the vaccinia virus or composition for inducing oncolysis in an individual having a tumor.
    Type: Application
    Filed: February 10, 2020
    Publication date: August 20, 2020
    Applicant: Ignite Immunotherapy, Inc.
    Inventors: David H. Kirn, Liliana Maruri Avidal, Prajit Limsirichai
  • RECOMBINANT VACCINIA VIRUS AND METHODS OF USE THEREOF
    Publication number: 20200222520
    Abstract: The present disclosure provides a replication-competent, recombinant oncolytic vaccinia virus; and compositions comprising the replication-competent, recombinant oncolytic vaccinia virus. The present disclosure also provides use of the vaccinia virus or composition for inducing oncolysis in an individual having a tumor.
    Type: Application
    Filed: January 9, 2020
    Publication date: July 16, 2020
    Applicant: Ignite Immunotherapy, Inc.
    Inventors: Douglas Hanahan, David H. Kirn, Liliana Maruri Avidal, Michael D. Eisenbraun, Joseph J. Binder, Clare Lees